Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Flagged first, then by citations

Show all 393 references

3 of the 393 references couldn’t be matched to a known paper.

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 401–500 of 998

Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine
Tybura, P., Trześniowska-Drukała, B., Bieńkowski, P., Beszłej, J. A., Frydecka, D., Mierzejewski, P., Samochowiec, A., Grzywacz, A., & Samochowiec, J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.039 · Cited by 24
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol
Parabiaghi, A., Tettamanti, M., D’Avanzo, B., Barbato, A., & the GiSAS study group (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12468 · Cited by 26
Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT6 and Dopamine D2 Receptor Ligands.
Krogsgaard‐Larsen, N., Jensen, A. A., Schrøder, T. J., Christoffersen, C. T., & Kehler, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003759 · Cited by 24
The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial
Wang, C., Shi, W., Huang, C., Zhu, J., Huang, W., & Chen, G. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0170-2 · Cited by 24
Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations
Huang, J., Hu, B., Xu, Z., Ye, Y., Wang, H., Wang, S., Liu, Z. L., & Wang, J. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04934-7 · Cited by 24
Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication
Strous, R. D., Greenbaum, L., Kanyas, K., Merbl, Y., Horowitz, A., Karni, O., Viglin, D., Olender, T., Deshpande, S. N., Lancet, D., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006651 · Cited by 24
Metabotropic glutamate receptor agonists for schizophrenia
Harrison, P. J. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.045088 · Cited by 24
Physical exercise down-regulated locomotor side effects induced by haloperidol treatment in Wistar rats.
Baptista, P. P. A., de Senna, P. N., Paim, M. F., Saur, L., Blank, M., do Nascimento, P., Ilha, J., Vianna, M. R. M., Mestriner, R. G., Achaval, M., et al. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.020 · Cited by 23
Antipsychotic drug-associated gene–miRNA interaction in T-lymphocytes
Gardiner, E. J., Carroll, A. P., Tooney, P. A., & Cairns, M. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001752 · Cited by 24
D2 receptor blockade eliminates exercise-induced changes in cortical inhibition and excitation
Curtin, D., Taylor, E. M., Bellgrove, M. A., Chong, T. T. ‐., & Coxon, J. P. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.04.019 · Cited by 23
CACNA1C gene and schizophrenia
Porcelli, S., Lee, S.-J., Han, C., Patkar, A. A., Serretti, A., & Pae, C. (2015) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000092 · Cited by 23
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first‐episode schizophrenia through 52 weeks follow‐up in China
Zhang, Y., & Dai, G. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2270 · Cited by 23
Integrated approaches to understanding antipsychotic drug action at GPCRs
Urs, N. M., NICHOLLS, P. J., & Caron, M. G. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.11.002 · Cited by 23
Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients
Greenbaum, L., Smith, R. C., Lorberboym, M., Alkelai, A., Zozulinsky, P., Lifschytz, T., Kohn, Y., Djaldetti, R., & Lerer, B. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2499-6 · Cited by 23
White Matter Abnormalities and Animal Models Examining a Putative Role of Altered White Matter in Schizophrenia
Xu, H., & Li, X. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/826976 · Cited by 23
Hypoactivity of the lateral habenula contributes to negative symptoms and cognitive dysfunction of schizophrenia in rats
Li, J., Yang, S., Liu, X., Han, Y., Li, Y., Feng, J., & Zhao, H. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.05.005 · Cited by 23
Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated
Luo, C., Lencer, R., Hu, N., Xiao, Y., Zhang, W., Li, S., Lui, S., & Gong, Q. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa061 · Cited by 23
Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
Bonito-Oliva, A., Feyder, M. T., & Fisone, G. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00038 · Cited by 24
The Effects of Ziprasidone, Clozapine and Haloperidol on Lipid Peroxidation in Human Plasma (in vitro): Comparison
Dietrich‐Muszalska, A., Kopka, J., & Kwiatkowska, A. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1050-z · Cited by 23
Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension
Gariépy, H. D. B., Carayon, P., Ferrari, B., & Couture, R. (2010) · Neuropeptides · doi:10.1016/j.npep.2009.12.011 · Cited by 23
NK3 receptor antagonists for the treatment of schizophrenia
Meltzer, H. Y., & Prus, A. J. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.11.013 · Cited by 23
N-Acetylaspartate Reduction in the Medial Prefrontal Cortex Following 8 weeks of Risperidone Treatment in First-Episode Drug-Naïve Schizophrenia Patients
Zong, X., Hu, M., Li, Z., Cao, H., Hé, Y., Liao, Y., Zhou, J., Sang, D., Zhao, H., Tang, J., et al. (2015) · Scientific Reports · doi:10.1038/srep09109 · Cited by 22
Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia
Elmorsy, E. M., Shahda, M., Mahmoud, E.-H. M., Rakha, S. A., & Shoaib, M. C. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115616385 · Cited by 22
Rhodiola rosea root extract has antipsychotic-like effects in rodent models of sensorimotor gating
Coors, A., Brosch, M., Kahl, E., Khalil, R., Michels, B., Laub, A., Franke, K., Gerber, B., & Fendt, M. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.02.031 · Cited by 22
Role of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice
Egashira, N., Shirakawa, A., Okuno, R., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.003 · Cited by 22
An investigation of the behavioral mechanisms of antipsychotic action using a drug–drug conditioning paradigm
Li, M., He, W., & Mead, A. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a8f66 · Cited by 22
Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism
Gao, J., & Li, M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.050 · Cited by 22
Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance
Vauquelin, G. (2012) · MedChemComm · doi:10.1039/c2md20015e · Cited by 22
Meta-analysis of polymorphism rs6311 and rs6313 in the5-HT2ARgene and schizophrenia
Li, S., Xu, P., Zhou, Y., Zuo, S., & Liu, Y. (2016) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2016.1217350 · Cited by 22
A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
Tsai, M. C., Chrones, L., Xie, J., Gevorkyan, H., & Macek, T. A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4412-9 · Cited by 22
The affinity of antipsychotic drugs to dopamine and serotonin 5-HT2 receptors determines their effects on prefrontal-striatal functional connectivity
Tollens, F., Gass, N., Becker, R., Schwarz, A. J., Risterucci, C., Künnecke, B., Lebhardt, P., Reinwald, J., Sack, M., Weber‐Fahr, W., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.05.016 · Cited by 27
Direct Brain Targeted Nanostructured Lipid Carriers for Sustained Release of Schizophrenic Drug: Formulation, Characterization and Pharmacokinetic Studies
Sivadasu, P., Gowda, D. V., Subramani, N. K., Vishweshwaraiah, B. M., Shivanna, S., & Siddaramaiah, H. (2019) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.54.1.9 · Cited by 22
A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson’s disease
Martı́nez, A., Ibarra, I. A., & Vargas, R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224691 · Cited by 22
Two new phenylpiperazines with atypical antipsychotic potential
Tomić, M., Ignjatović, Đ., Tovilović-Kovačević, G., Andrić, D. B., Roglić, G., & Kostić‐Rajačić, S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.066 · Cited by 22
Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
Neuropharmacology of altered brain oscillations in schizophrenia
Koch, M., Schmiedt‐Fehr, C., & Mathes, B. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.02.014 · Cited by 21
Histamine H4 Receptor Polymorphism
Wei, Z., Wang, L., Yu, T., Wang, Y., Sun, L., Ti, W., Huo, R., Li, Y., Wu, X., Qin, S., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318283963b · Cited by 21
Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function
Chavez-Noriega, L. E., Marino, M. J., Schaffhauser, H., Campbell, U. C., & Conn, P. J. (2005) · Current Neuropharmacology · doi:10.2174/1570159052773369 · Cited by 21
Hypothalamic–pituitary–adrenal system, neurotrophic factors and clozapine response
Mitjans, M., Catalán, R., Vázquez, M., González-Rodríguez, A., Penadés, R., Pons, A., Massana, G., Munro, J., Arranz, M. J., & Arias, B. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000132 · Cited by 22
Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats
Kurşungöz, C., Ak, M., & Yanık, T. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.070 · Cited by 21
Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders
Teal, L. B., Gould, R. W., Felts, A. S., & Jones, C. K. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.05.001 · Cited by 20
Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling
Jordan, S., Johnson, J. L., Regardie, K., Chen, R., Koprivica, V., Tadori, Y., Kambayashi, J., Kitagawa, H., & Kikuchi, T. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.09.007 · Cited by 21
Asenapine
Meltzer, H. Y., Dritselis, A., Yasothan, U., & Kirkpatrick, P. N. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3027 · Cited by 21
Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kishi, T., & Iwata, N. (2013) · CNS Drugs · doi:10.1007/s40263-013-0085-7 · Cited by 20
LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment
Li, M.-L., Yang, S.-S., Xing, B., Ferguson, B. R., Gulchina, Y., Li, Y.-C., Li, F., Hu, X.-Q., & Gao, W. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.019 · Cited by 19
Antipsychotic and Anticholinergic Drug Prescribing Pattern in Psychiatry: Extent of Evidence-Based Practice in Bahrain
Khaja, K. A. J. A., Al-Haddad, M. K., Sequeira, R. P., & Al-Offi, A. R. (2012) · Pharmacology & Pharmacy · doi:10.4236/pp.2012.34055 · Cited by 20
CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors
Cortés, M., Malave, L. B., Castelló, J., Flajolet, M., Cenci, M. A., Friedman, E., & Rebholz, H. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0443-17.2017 · Cited by 20
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia
Hopper, S., Pavey, G., Gogos, A., & Dean, B. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz045 · Cited by 20
The Promise and Reality of Pharmacogenetics in Psychiatry
Zandi, P. P., & Judy, J. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.07.004 · Cited by 20
T102C polymorphism of serotonin 2 A type receptor gene confers susceptibility to (early onset) schizophrenia in H an C hinese: An association study and meta‐analysis
Ni, J., Lu, W., Wu, Z., Chen, J., Yi, Z., & Zhang, C. (2013) · Asia-Pacific Psychiatry · doi:10.1111/appy.12027 · Cited by 20
Extrapyramidal Symptoms Probably Related to Risperidone Treatment: A Case Series
Thomson, S. R., Chogtu, B., Bhattacharjee, D., & Agarwal, S. (2017) · Annals of Neurosciences · doi:10.1159/000477153 · Cited by 20
Herb‐drug interactions: A short review on central and peripheral nervous system drugs
Bernardo, J., & Valentão, P. (2024) · Phytotherapy Research · doi:10.1002/ptr.8120 · Cited by 21
Genetic association analysis of N‐methyl‐ d ‐aspartate receptor subunit geneGRIN2Band clinical response to clozapine
Taylor, D. L., Tiwari, A. K., Lieberman, J. A., Potkin, S. G., Meltzer, H. Y., Knight, J., Remington, G. J., Müller, D. J., & Kennedy, J. L. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2519 · Cited by 20
Self-citation
Corpus callosum volumes in the 5 years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation
de Moura, M. T. M., Zanetti, M. V., Duran, F., Schaufelberger, M. S., Menezes, P. R., Scazufca, M., Busatto, G. F., & Serpa, M. H. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.03.015 · Cited by 20
The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study
Hakami, A. Y., Felemban, R. A., Ahmad, R. G., Alsamadani, A. H., Salamatullah, H. K., Baljoon, J. M., Alghamdi, L. J., Sindi, M. H. R., & Ahmed, M. E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.914165 · Cited by 19
New insight in the cross-talk between microglia and schizophrenia: From the perspective of neurodevelopment
Li, J., Wang, Y., Yuan, X., Kang, Y., & Song, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1126632 · Cited by 19
Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice
Oh, H. K., Park, S. J., Bae, S. G., Kim, M. J., Jang, J. H., Ahn, Y. J., Woo, H., Kwon, G., & Ryu, J. H. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.01.032 · Cited by 19
A pharmacogenetic study of risperidone on histamine H3 receptor gene ( HRH3 ) in Chinese Han schizophrenia patients
Wei, Z., Wang, L., Zhang, M., Xuan, J., Wang, Y., Liu, B., Shao, L., Li, J., Zeng, Z., Li, T., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111405358 · Cited by 19
In vivo quantification of striatal dopamine D 2 receptor occupancy by JNJ-37822681 using [ 11 C]raclopride and positron emission tomography
Beek, E. T. T., de Boer, P., Moerland, M., Schmidt, M. E., Hoetjes, N. J., Windhorst, A. D., van Berckel, B. N. M., Cohen, A. F., van Gerven, J. M., & Lammertsma, A. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111435251 · Cited by 19
D-Amphetamine and Antipsychotic Drug Effects on Latent Inhibition in Mice Lacking Dopamine D2 Receptors
Bay-Richter, C., O’Callaghan, M. J., Mathur, N., O’Tuathaigh, C. M. P., Heery, D. M., Fone, K. C. F., Waddington, J. L., & Moran, P. M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.50 · Cited by 19
Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems
Rossi, P. D., Chiapponi, C., & Spalletta, G. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150507223542 · Cited by 19
Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia
Li, M. S., Gulchina, Y., Monaco, S. A., Xing, B., Ferguson, B. R., Li, Y., Li, F., Hu, X., & Gao, W. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.02.004 · Cited by 19
Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia
Takase, S., Liao, J., Liu, Y., Tanaka, R., Miyagawa, Y., Sawahata, M., Sobue, A., Mizoguchi, H., Nagai, T., Kaibuchi, K., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175207 · Cited by 19
Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes
Hu, M., Xia, Y., Zong, X., Sweeney, J. A., Bishop, J. R., Liao, Y., Giase, G. M., Li, B., Rubin, L. H., Wang, Y., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114789 · Cited by 19
Neuroimmune Pharmacology of Neurodegenerative and Mental Diseases
Shie, F., Chen, Y., Chen, C., & Ho, I.-K. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9241-8 · Cited by 19
Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum
Pereira, A. M., Zhang, B., Malcolm, P., & Sundram, S. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.025 · Cited by 19
Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction
Cai, J., Yi, Z., Lu, W., Fang, Y., & Zhang, C. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.01.012 · Cited by 19
Behavioral and Metabolic Effects of the Atypical Antipsychotic Ziprasidone on the Nematode Caenorhabditis elegans
Gubert, P., Aguiar, G. C., Mourão, T., Bridi, J. C., Barros, A. G. D. A., Soares, F. A. A., & Romano‐Silva, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074780 · Cited by 19
Regulation of neutrophil phagocytosis of Escherichia coli by antipsychotic drugs
Chen, M., Wu, S., Tsai, T., Wang, L.-K., & Tsai, F. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.09.030 · Cited by 19
Differential Long-Term Effects of Haloperidol and Risperidone on the Acquisition and Performance of Tasks of Spatial Working and Short-Term Memory and Sustained Attention in Rats
Hutchings, E. J., Waller, J. L., & Terry, A. V. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.209031 · Cited by 19
Proteomics of membrane receptors and signaling
Kabbani, N. (2008) · PROTEOMICS · doi:10.1002/pmic.200800139 · Cited by 19
Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine
Poddar, I., Callahan, P. M., Hernandez, C. M., Yang, X., Bartlett, M. G., & Terry, A. V. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.017 · Cited by 18
Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics
Gao, L., Hao, C., Ma, R., Chen, J., Zhang, G., & Chen, Y. (2021) · RSC Advances · doi:10.1039/d1ra02426d · Cited by 18
Ketamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model
Maltbie, E. A., Gopinath, K., Urushino, N., Kempf, D., & Howell, L. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4175-8 · Cited by 18
Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment
Chen, C., Yeh, Y., Kuo, S.-C., Ho, P., Liang, C., Yen, C.-H., Lu, R., & Huang, S. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.12.003 · Cited by 18
First-Generation Antipsychotic Haloperidol Alters the Functionality of the Late Endosomal/Lysosomal Compartment in Vitro
Canfrán‐Duque, A., Barrio, L. C., Lerma, M., de la Peña, G., Serna, J., Pastor, Ó., Lasunción, M. A., & Busto, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030404 · Cited by 18
3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT2B, 5-HT7, or σ1 Receptor Ligands
Porter, M. R., Xiao, H., Wang, J., Smith, S. B., & Topczewski, J. J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00225 · Cited by 19
Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment
Young, J. W., Roberts, B. Z., Breier, M. R., & Swerdlow, N. R. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05511-1 · Cited by 18
Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment
Luoni, A., da Rocha, F. F., & Riva, M. A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.008 · Cited by 18
Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)
Hu, E., Kunz, R. K., Rumfelt, S., Andrews, K. L., Li, C., Hitchcock, S. A., Lindström, M., & Treanor, J. J. S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.010 · Cited by 18
Chronic administration of risperidone to healthy rats: A behavioural and morphological study
Castellano, O., Moscoso, A., Riolobos, A. S., Carro, J., Arji, M., Molina, V., López, D. E., & Sancho, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.08.002 · Cited by 18
Clozapine inhibits development and expression of nicotine‐induced locomotor sensitization in rats
Kayır, H., Göktalay, G., Yildirim, M., & Uzbay, T. I. (2008) · Synapse · doi:10.1002/syn.20576 · Cited by 18
Priapism in Antipsychotic Drug Use: A Rare but Important Side Effect
Sinkeviciute, I., Kroken, R. A., & Johnsen, E. (2012) · Case Reports in Psychiatry · doi:10.1155/2012/496364 · Cited by 20
Dipyridamole monotherapy in schizophrenia
Wonodi, I., Gopinath, H. V., Liu, J., Adami, H. M., Hong, L. E., Allen-Emerson, R., McMahon, R. P., & Thaker, G. K. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2315-3 · Cited by 18
Evidence for Neuroprotective Effects of Antipsychotic Drugs: Implications for the Pathophysiology and Treatment of Schizophrenia
LI, X., & Xu, H. (2006) · International review of neurobiology · doi:10.1016/s0074-7742(06)77004-0 · Cited by 18
Beneficial effects of cannabidiol from Cannabis
Lee, S., Lee, Y., Kim, Y., Kim, H. J., Rhyu, H., Yoon, K. M., Lee, C.-D., & Lee, S. (2024) · Applied Biological Chemistry · doi:10.1186/s13765-024-00867-w · Cited by 17
Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia
Maini, K., Hollier, J. W., Gould, H., Bollich, V., LaForge, J., Cornett, E. M., Edinoff, A. N., Kaye, A. M., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.24932 · Cited by 19
Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia
Álvarez-Herrera, S., Rosel-Vales, M., Pérez‐Sánchez, G., Becerril‐Villanueva, E., Flores-Medina, Y., Maldonado-García, J. L., Saracco-Álvarez, R. A., Escamilla-Orozco, R. I., & Pavón, L. (2024) · Pharmaceuticals · doi:10.3390/ph17020167 · Cited by 17
Chemistry-based molecular signature underlying the atypia of clozapine
Cardozo, T. J., Shmelkov, E., Felsövályi, K., Swetnam, J., Butler, T., Malaspina, D., & Shmelkov, S. V. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.6 · Cited by 16
Spirulina platensis reduces the schizophrenic-like symptoms in rat model by restoring altered APO-E and RTN-4 protein expression in prefrontal cortex
Haider, S., Shahzad, S., Batool, Z., Sadir, S., Liaquat, L., Tabassum, S., & Perveen, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119417 · Cited by 19
Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?
Qiao, J., Gao, J., Shu, Q., Zhang, Q., Hu, G., & Li, M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3386-0 · Cited by 17
Using prepulse inhibition to detect functional D3 receptor antagonism: Effects of WC10 and WC44
Weber, M., Chang, W.-L., Durbin, J. P., Park, P. E., Luedtke, R. R., Mach, R. H., & Swerdlow, N. R. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.022 · Cited by 17
How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses
Marques, T. R., Levine, S. Z., Reichenberg, A., Kahn, R. S., Derks, E. M., Fleischhacker, W., Rabinowitz, J., & Kapur, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.04.001 · Cited by 17
Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA)
Fragoso, V. M. D. S., Hoppe, L. Y., de Araújo-Jorge, T. C., de Azevedo, M. J., Campos, J. D. D. S., Cortez, C. M., & de Oliveira, G. M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.12.010 · Cited by 17
Treatment with Piribedil and Memantine Reduces Noise-Induced Loss of Inner Hair Cell Synaptic Ribbons
Altschuler, R. A., Wys, N. L., Prieskorn, D. M., Martin, C., DeRemer, S. J., Bledsoe, S. C., & Miller, J. M. (2016) · Scientific Reports · doi:10.1038/srep30821 · Cited by 17
The 5α-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia
Maurice‐Gelinas, C., Deslauriers, J., Monpays, C., Sarret, P., & Grignon, S. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.03.036 · Cited by 17
Clozapine-induced transcriptional changes in the zebrafish brain
Viana, J. F., Wildman, N., Hannon, E. J., Farbos, A., Neill, P. O., Moore, K., van Aerle, R., Paull, G. C., Santos, E. M., & Mill, J. S. (2020) · Schizophrenia · doi:10.1038/s41537-019-0092-x · Cited by 17
Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex
Farrelly, L. A., Dicker, P., Wynne, K. J., English, J., Cagney, G., Föcking, M., & Cotter, D. (2014) · PROTEOMICS · doi:10.1002/pmic.201300466 · Cited by 16
Aripiprazole for the treatment of delusional disorders: A systematic review
Miola, A., Salvati, B., Sambataro, F., & Toffanin, T. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.06.012 · Cited by 16
Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review
Couttas, T. A., Jieu, B., Rohleder, C., & Leweke, F. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.885904 · Cited by 17

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks